NCT04361825 (SUKSES-N4) is a Phase 2 clinical trial of Durvalumab in Small Cell Lung Cancer, sponsored by Se-Hoon Lee.

Who is sponsoring NCT04361825?

NCT04361825 is sponsored by Se-Hoon Lee.

What drugs are being tested in NCT04361825?

Interventions in NCT04361825: Durvalumab.

What condition does NCT04361825 study?

NCT04361825 studies Small Cell Lung Cancer.

Is NCT04361825 still recruiting?

NCT04361825 is currently completed. Last updated 3 January 2024.

Last reviewed 2024-01-03 · How we verify

NCT04361825: SUKSES-N4

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects

Completed Phase 2 Last updated 3 January 2024

What this trial tests

Phase 2 trial testing Durvalumab in Small Cell Lung Cancer in 42 participants. Completed in 25 October 2023.

Timeline

17 June 2020

Primary endpoint
25 October 2023

25 October 2023

Quick facts

Lead sponsor	Se-Hoon Lee
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	42
Start date	17 June 2020
Primary completion	25 October 2023
Estimated completion	25 October 2023
Sites	2 locations across South Korea

Drugs / interventions tested

Durvalumab — full drug profile →

Conditions studied

Small Cell Lung Cancer — all drugs for Small Cell Lung Cancer →

Sponsor

Se-Hoon Lee — full company profile →

Who can join

18 and older, any sex, with Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single arm, multi-center phase II study of durvalumab and AZD6738 combination therapy in subjects with relapsed small cell lung cancer (SCLC) as a second or third line chemotherapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

DNA Repair Pathways in Cancer Therapy and Resistance.
Li LY, Guan YD, Chen XS, Yang JM, et al · · 2020 · cited 254× · PMID 33628188 · DOI 10.3389/fphar.2020.629266
Emerging strategies for cancer therapy by ATR inhibitors.
Yano K, Shiotani B. · · 2023 · cited 42× · PMID 37189251 · DOI 10.1111/cas.15845
Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets.
Khamidullina AI, Abramenko YE, Bruter AV, Tatarskiy VV. · · 2024 · cited 34× · PMID 38279263 · DOI 10.3390/ijms25021263
Targeting the DNA damage response for cancer therapy.
Curtin NJ. · · 2023 · cited 30× · PMID 36606678 · DOI 10.1042/bst20220681
Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target.
Raimundo L, Calheiros J, Saraiva L. · · 2021 · cited 23× · PMID 34298653 · DOI 10.3390/cancers13143438
Targeting ATR Pathway in Solid Tumors: Evidence of Improving Therapeutic Outcomes.
Mavroeidi D, Georganta A, Panagiotou E, Syrigos K, et al · · 2024 · cited 14× · PMID 38474014 · DOI 10.3390/ijms25052767
Toxicities of Immunotherapy for Small Cell Lung Cancer.
Fu Y, Zheng Y, Wang PP, Ding ZY. · · 2021 · cited 9× · PMID 34136376 · DOI 10.3389/fonc.2021.603658
Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities.
Zhang J, Zeng X, Guo Q, Sheng Z, et al · · 2024 · cited 8× · PMID 39103941 · DOI 10.1186/s40164-024-00548-w

Verify or expand the search:

Other trials of Durvalumab

Trials testing the same drug.

NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT07459634 — A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC · Phase 2 · not yet recruiting

Other recruiting trials for Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
NCT07296809 — SKB500 Combinations in Patients With Small Cell Lung Cancer · Phase 2 · recruiting
NCT07155200 — Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) · Phase 1, PHASE2 · recruiting
NCT06922539 — ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer · Phase 1 · recruiting
NCT07373964 — A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD · Phase 2 · recruiting

Other Se-Hoon Lee trials

Trials by the same sponsor.

NCT07432984 — Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC · Phase 2 · not yet recruiting
NCT06830694 — Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizum · Phase 2 · recruiting
NCT05463224 — Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients · Phase 2 · active not recruiting
NCT04939662 — Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects · Phase 2 · completed
NCT04525391 — AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04361825 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Se-Hoon Lee
Last refreshed: 3 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04361825.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing